Claims for Patent: 5,756,349

Summary for Patent: 5,756,349

Title:	Production of erythropoietin
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of mammalian erythropoietin (\"EPO\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Illustratively, genomic DNA, cDNA and manufactured DNA sequences coding for part or all of the sequence of amino acid residues of EPO or for analogs thereof are incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Upon isolation from culture media or cellular lysates or fragments, products of expression of the DNA sequences display, e.g., the immunological properties and in vitro and in vivo biological activities of EPO of human or monkey species origins. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of EPO. Also disclosed are improved methods for the detection of specific single stranded polynucleotides in a heterologous cellular or viral sample prepared from, e.g., DNA present in a plasmid or viralborne cDNA or genomic DNA \"library\".
Inventor(s):	Lin; Fu-Kuen (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	08/468,369
Patent Claims:	1. Vertebrate cells which can be propagated in vitro and which are capable upon growth in culture of producing erythropoietin in the medium of their growth in excess of 100 U of erythropoietin per 10.sup.6 cells in 48 hours as determined by radioimmunoassay, said cells comprising non-human DNA sequences which control transcription of DNA encoding human erythropoietin. 2. Vertebrate cells according to claim 1 capable of producing in excess of 500 U erythropoietin per 10.sup.6 cells in 48 hours. 3. Vertebrate cells according to claim 1 capable of producing in excess of 1000 U erythropoietin per 10.sup.6 cells in 48 hours. 4. Vertebrate cells which can be propagated in vitro which comprise transcription control DNA sequences, other than human erythropoietin transcription control sequences, for production of human erythropoietin, and which upon growth in culture are capable of producing in the medium of their growth in excess of 100 U of erythropoietin per 10.sup.6 cells in 48 hours as determined by radioimmunoassay. 5. Vertebrate cells according to claim 4 capable of producing in excess of 500 U erythropoietin per 10.sup.6 cells in 48 hours. 6. Vertebrate cells according to claim 4 capable of producing in excess of 1000 U erythropoietin per 10.sup.6 cells in 48 hours. 7. A process for producing erythropoietin comprising the step of culturing, under suitable nutrient conditions, vertebrate cells according to claim 1, 2, 3, 4, 5 or 6.

Details for Patent 5,756,349

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234	June 01, 1989	5,756,349	2015-05-26
Amgen Inc.	EPOGEN/PROCRIT	epoetin alfa	Injection	103234		5,756,349	2015-05-26
Amgen Inc.	PROCRIT	epoetin alfa	Injection	103234		5,756,349	2015-05-26

International Patent Family for US Patent 5,756,349

Country	Patent Number	Estimated Expiration
South Africa	849625
World Intellectual Property Organization (WIPO)	8502610
United States of America	5955422
United States of America	5621080
United States of America	5618698
United States of America	5547933